Pharmacological miR-155 blockade restricts neurodegenerative pathology and preserves cognitive function in AD
March 13, 2024
In a new study, researchers from Harvard Medical School and Regulus Therapeutics Inc. further investigated the role of miR-155 in Alzheimer's disease (AD).
